Additional groups that signed the coalition letter include American Commitment, Americans for Tax Reform,
VIEW PDF OF LETTER (http://pdf.iwf.org/TF_TPA_FDA_Coalition_Letter.pdf)
The Honorable Dr.
Dear Administrator Gottlieb,
We the undersigned organizations dedicated to improving public health and reducing taxpayers' burden through innovation, congratulate you on your confirmation to chair the
The world is moving from analog to digital in almost every aspect. Wearable tech like
The tobacco market has experienced a similar tech-driven disruption. Over the past decade, electronic vapor (aka e-cigarettes) has evolved from a marginal novelty to a significant part of the lives of Americans across the spectrum as they seek out safer and better nicotine-delivery alternatives. As millions switch from smoking to vaping, the mass movement from a harmful analog product--cigarettes-- to demonstrably safer digitized products should be celebrated as a development with the potential to improve and save millions of lives.
Despite the success of educational campaigns on the harms of tobacco use, cessation efforts have hit a plateau, with a portion of the population unable to kick their deadly habit. We recognize that quitting tobacco use is a complex and personal challenge; what works for some may not work for all. This effort demands an all-of-theabove approach. As we noted in a previous letter to
The world has made enormous progress in reducing smoking. Decades of improvements in education, research, and cessation methods have helped reduce the percentage of smokers in the US from 42.4% in 1965 to 15.1% today. Despite those efforts, nearly 40 million Americans and a billion people worldwide still smoke -- most in low and middle-income countries that are hit harder by tobacco-related illness. How the
requires e-vapor product manufacturers to endure a lengthy and expensive pre-market tobacco application process for all products not brought to market before the predicate date of
We hope that under your leadership, the
We further request a meeting with you or your designee to discuss these concerns.
The Honorable Dr.
Director of the